Jump Financial LLC Purchases 114,005 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Jump Financial LLC lifted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 144.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 192,708 shares of the biotechnology company's stock after buying an additional 114,005 shares during the quarter. Jump Financial LLC owned 0.39% of REGENXBIO worth $1,490,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Walleye Capital LLC acquired a new position in REGENXBIO during the 4th quarter valued at about $681,000. XTX Topco Ltd raised its position in REGENXBIO by 720.5% during the fourth quarter. XTX Topco Ltd now owns 108,120 shares of the biotechnology company's stock valued at $836,000 after buying an additional 94,943 shares during the period. Barclays PLC grew its stake in REGENXBIO by 9.5% during the 4th quarter. Barclays PLC now owns 127,065 shares of the biotechnology company's stock valued at $982,000 after acquiring an additional 11,041 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of REGENXBIO during the 4th quarter valued at $568,000. Finally, Renaissance Technologies LLC bought a new stake in REGENXBIO in the fourth quarter worth approximately $2,097,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Morgan Stanley increased their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. HC Wainwright cut their price target on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. Royal Bank of Canada restated an "outperform" rating and issued a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Finally, Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Stock Performance

NASDAQ RGNX traded up $0.33 on Thursday, reaching $9.20. The company had a trading volume of 838,445 shares, compared to its average volume of 814,389. The firm has a market capitalization of $461.08 million, a price-to-earnings ratio of -1.83 and a beta of 1.26. The company's fifty day moving average is $6.84 and its 200-day moving average is $8.12. REGENXBIO Inc. has a 1-year low of $5.04 and a 1-year high of $17.52.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. On average, research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.